Endometriosis is a common and painful condition affecting women of reproductive age. While the underlying pathophysiology is still largely unknown, much advancement has been made in understanding the progression of the disease. In recent years, a great deal of research has focused on non-invasive diagnostic tools, such as biomarkers, as well as identification of potential therapeutic targets. In this article, we will review the etiology and cellular mechanisms associated with endometriosis as well as the current diagnostic tools and therapies. We will then discuss the more recent genomic and proteomic studies and how these data may guide development of novel diagnostics and therapeutics. The current diagnostic tools are invasive and current therapies primarily treat the symptoms of endometriosis. Optimally, the advancement of “-omic” data will facilitate the development of non-invasive diagnostic biomarkers as well as therapeutics that target the pathophysiology of the disease and halt, or even reverse, progression. However, the amount of data generated by these types of studies is vast and bioinformatics analysis, such as we present here, will be critical to identification of appropriate targets for further study.

Stress urinary incontinence (SUI) significantly diminishes the quality of patients' lives. Currently available surgical and nonsurgical therapies remain far from ideal. At present, advances in cellular technologies have stirred growing interest in the use of autologous cell treatments aimed to regain urinary control. The objective was to conduct a review of the literature and analyse preclinical and clinical studies dedicated to various cell therapies for SUI, assessing their effectiveness, safety, and future prospects. A systematic literature search in PubMed was conducted using the following key terms: "stem," "cell," "stress," "urinary," and "incontinence." A total of 32 preclinical studies and 15 clinical studies published between 1946 and December 2014 were included in the review. Most preclinical trials have used muscle-derived stem cells and adipose-derived stem cells. However, at present, the application of other types of cells, such as human amniotic fluid stem muscle-derived progenitor cells and bone marrow mesenchymal stromal cells, is becoming more extensive. While the evidence shows that these therapies are effective and safe, further work is required to standardize surgical techniques, as well as to identify indications for their use, doses and number of doses. Future research will have to focus on clinical applications of cell therapies; namely, it will have to determine indications for their use, doses of cells, optimal surgical techniques and methods, attractive cell sources, as well as to develop clinically relevant animal models and make inroads into understanding the mechanisms of SUI improvement by cell therapies.

No abstract

There are patients suffered prostate cancer and diagnosed with stone disease in urological centres. These cases represent non-standard issue of choosing the optimal surgical treatment. Currently clinical recommendations haven’t described the particular answer for this answer yet. There is also lack of information published in literature foсused on the issue.Aim of the study was to determine the optimal choice of surgical treatment for patients diagnosed with stone disease and prostate cancer.Materials and methods: Retrospective study of patients diagnosed with prostate cancer and stone disease for the period from 2006 to 2019 was performed. Among 2047 in-patient cases of prostate cancer 71 patients with stone disease were included.Results: 49 of 71 (69%) patients diagnosed with stone disease had indications for surgical treatment at the moment of hospitalisation. Stages of prostate cancer in this group were T1-T2 (91,7%) and T3(8,3%). 25 patients (51%) had kidney stone disease, 23 patients (47%) – ureter stone disease and only 1 patient – kidney and ureter stone disease. 37 patients (75%) presented complains related to stone disease, other cases (25%) were asymptomatic. Surgical treatment of stone disease primarily was performed in the majority of cases (72,2%). Surgical treatment of prostate cancer subsequently included radical prostatectomy in most cases 7 (86,1%). Simultaneous surgical treatment of both diseases haven’t performed in this study.Conclusion: The main factors influencing the decision making of optimal surgical treatment for this group of patients were clinical presentation and group of prostate cancer risk.